0000000000068945

AUTHOR

Raffaella Stocchi

showing 2 related works from this author

Elotuzumab, lenalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: Italian, multicenter, retrospective clinical exper…

2020

No abstract available

Oncologymedicine.medical_specialtyElotuzumab lenalidomide dexamethasone salvage therapy multiple myelomaSalvage therapyAntibodies Monoclonal HumanizedAntibodiesDexamethasoneEfficacyInternal medicineMonoclonalAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansProgression-free survivalElotuzumabLetters to the EditorElotuzumab lenalidomide dexamethasone multiple myelomaHumanizedLenalidomideMultiple myelomaRetrospective StudiesLenalidomideSalvage Therapybusiness.industryRetrospective cohort studyHematologymedicine.diseaseClinical trialItalyAntibodies Monoclonal Humanized; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Italy; Lenalidomide; Retrospective Studies; Salvage Therapy; Multiple MyelomaMultiple Myelomabusinessmedicine.drug
researchProduct

Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 3‐year follow‐up of a multicenter, retrospective cli…

2022

: The combination of elotuzumab, lenalidomide, and dexamethasone (EloRd) enhanced the clinical benefit over Rd with a manageable toxicity profile in the ELOQUENT-2 trial, leading to its approval in relapsed/refractory multiple myeloma (RRMM). The present study is a 3-year follow-up update of a previously published Italian real-life RRMM cohort of patients treated with EloRd. This revised analysis entered 319 RRMM patients accrued in 41 Italian centers. After a median follow-up of 36 months (range 6-55), 236 patients experienced disease progression or died. Median progression-free survival (PFS) and overall survival (OS) were 18.4 and 34 months, respectively. The updated multivariate analyse…

Cancer Researchlenalidomidedexamethasone; elotuzumab; lenalidomide; multiple myeloma; salvage therapydexamethasoneHematologyGeneral MedicineAntibodies Monoclonal HumanizedelotuzumabThalidomidemultiple myelomaOncologyAntineoplastic Combined Chemotherapy ProtocolsHumanssalvage therapySettore MED/15 - Malattie del SangueFollow-Up StudiesRetrospective StudiesHematological Oncology
researchProduct